Autonomix launches GLP study for Sensing and RF ablation system

Autonomix (AMIX) “announced that it has commenced a Good Laboratory Practice (GLP) preclinical study required by the FDA at CBSET, a state-of-the-art pre-clinical translational research institute, for its Sensing and RF Ablation System as a treatment for pancreatic cancer pain. This GLP study is a set of quality standards that Autonomix is following to ensure the reliability and integrity of its devices in order to meet regulatory requirements for submitting data to the FDA for IDE clinical trials and product approval.”